Search

everythinglearnresearchcommunity

for

Search:↓

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

After chemotherapy for early breast cancer, 33.4% of patients had long-term significant hair loss, with some hair regrowth over time, but treatments for hair loss were largely ineffective.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Hair from breast cancer patients shows changes in structure and composition, and a test using these changes detected cancer but also falsely identified some healthy samples as cancerous.

X-ray diffraction of hair might help detect breast cancer non-invasively.

Xiaoaiping reduces chemotherapy side effects and improves quality of life for breast cancer patients.

ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.

Minoxidil and ranolazine together can reduce the spread of certain breast cancer cells.

The conclusion is that thorough investigation of hypertension and hormonal dysfunctions is important, and there may be a link between these conditions and cancer.

The paper concludes that breast cancer treatment involves complex interactions between medical symptoms, patient experiences, and commercial influences, requiring a holistic approach.

Radiation therapy in breast cancer patients changes gene expression related to DNA damage, fibroblast growth, and hair follicle development, which could help improve treatment for radiation-induced fibrosis.

Docetaxel treatment for breast cancer can cause permanent hair loss.

Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.

Scalp cooling is largely ineffective in preventing hair loss from breast cancer chemotherapy.

Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.

Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.

Madarosis (eyebrow and eyelash loss) significantly affects quality of life for breast cancer patients on taxane-based chemotherapy.

Different types of persistent hair loss after chemotherapy respond differently to treatments.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Using certain hair products may increase breast cancer risk in black women.

Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.

Reproductive hormones play a crucial role in breast cancer development and treatment challenges.

Low-dose oral minoxidil combined with topical minoxidil improves hair growth in breast cancer patients with therapy-induced hair loss.

Semecarpus anacardium leaf extract fights breast cancer and extends survival in mice.